MedTrace Logo

GS1-144 in Participants With Hepatic Impairment and Healthy Female

NCT07491289 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-03-24

No results posted yet for this study

Summary

GS1-144 in Participants with Hepatic Impairment and Healthy Female

Conditions

  • Hepatic Impairment and Healthy Female

Interventions

DRUG

GS1-144 tablet

Administered a single oral dose with GS1-144 tablet 30mg

Sponsors & Collaborators

  • Changchun GeneScience Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-20
Primary Completion
2027-01-31
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07491289 on ClinicalTrials.gov